Aptorum Group LTD 8-K filings

Niki BioSolutions, Inc. has appointed Thomas Freeburg as its new Chief Financial Officer, detailing his compensation package and responsibilities.

Niki BioSolutions, Inc. has entered into an At the Market Offering Agreement to sell up to $1,396,000 of its common stock through H.C. Wainwright & Co., LLC and Brookline Capital Markets.

Niki BioSolutions, Inc. (NIKI) has filed an 8-K detailing its corporate PowerPoint presentation, outlining the completion of its merger with Aptorum Group and its subsidiary DiamiR Biosciences, and presenting its strategic vision focused on Alzheimer's disease diagnostics and therapeutics.

Niki BioSolutions, Inc. has officially appointed Ian Huen as CEO and Alidad Mireskandari as President and COO, detailing their compensation and equity awards following a merger.

Niki BioSolutions, Inc. (formerly Aptorum Group Limited) has filed an amendment to its Form 8-K to include the audited financial statements of DiamiR Biosciences Corp. following their merger.

Niki BioSolutions, Inc. (formerly Aptorum Group Limited) has filed its Form 8-K, providing interim financial statements post-merger with DiamiR Biosciences Corp. and highlighting ongoing financial challenges.

Niki BioSolutions, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing at $1.00 or greater for ten consecutive business days.

Niki BioSolutions, Inc. (formerly Aptorum Group Limited) and DiamiR Biosciences Corp. have completed their merger, establishing a new entity focused on biopharmaceutical and diagnostics.